Pfizer Discontinues Hemophilia Gene Therapy Beqvez As Interest Wanes
According to multiple media reports on Thursday, Pfizer Inc. (NYSE:PFE) has terminated the global development and ...
Pharma giant's pullback from gene therapy puts spotlight on North Carolina operations
One of the largest pharmaceutical companies in North Carolina is discontinuing a treatment produced in the state.
devdiscourse21h
Disruptions in Health: US Aid Freeze, Rising Measles, and Big Pharma Moves
US aid freeze affects HIV and malaria supply chains, FDA postpones rare disease events, and a leap in Texas measles cases. Meanwhile, Mirum Pharma's drug gets FDA approval, Eli Lilly invests in a ...
Cell And Gene Therapies In Rare Disorders Market To Skyrocket Across The 7MM During The Forecast Period (2025–2034) | Delveinsight
The cell and gene therapies in rare disorders market is expected to grow at a significantly high rate during the forecast period (2025–2034) and main ...
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.
What's Going On With Cancer Diagnostic Firm Guardant Health On Friday?
Guardant Health (NYSE:GH) reported fourth-quarter adjusted EPS loss of 62 cents, compared to a loss of 64 cents a year ago, ...